The Rabies Diagnostics Market Global Outlook is fundamentally shaped by the ambitious "Zero by 30" global strategic plan, a collaboration between the World Health Organization (WHO), the World Organisation for Animal Health (OIE), the Food and Agriculture Organization of the United Nations (FAO), and the Global Alliance for Rabies Control (GARC). This plan aims to eliminate human deaths from dog-mediated rabies by the year 2030. Achieving this goal requires a unified 'One Health' approach, integrating human public health and veterinary animal health programs, with diagnostics serving as the critical link. The global outlook for the market is therefore one of sustained high demand, particularly for affordable and easy-to-use tools that facilitate surveillance in mass dog vaccination campaigns.

Diagnostics are crucial for three main reasons within this framework: first, confirming human cases to ensure appropriate end-of-life care and to investigate the exposure source; second, confirming animal rabies to guide post-exposure prophylaxis for exposed humans; and third, as a core surveillance tool to monitor the impact of vaccination programs in animal populations. The elimination agenda places a premium on diagnostics that can operate effectively in challenging field environments and deliver rapid results to inform policy. The global market is thus being driven by an ethical imperative and a public health mandate, which collectively ensure continuous investment and a positive long-term growth trajectory across all geographic $\text{Rabies Diagnostics Market}$s.